USPTO 2015–2025 USPTO PatentsView Foreign Corporation

KPC Pharmaceuticals, Inc

USPTO PatentsView assignee record - 5 granted patents across 8 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, KPC ranks #48,221 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 8 technology areas.

#48,221
of 49,997 US assignees by volume
Top 42%
by Innovation Score (37.9/100)
14.0
avg claims per patent
+0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R48221 · Foreign Corporation #48,221 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #48,221/49,997
  • PHOTO-FINISH Korea (CENTER FOR…
  • CPC-NARROW A61P · 8 areas
  • INNOV-THIN 37.9/100
  • CLAIMS-RICH 14.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-FLAT +0% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Korea (CENTER FOR Disease Control AND PREVENTION) (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around KPC

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows KPC's Innovation Score is 37.9/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where KPC's grants concentrate

KPC Pharmaceuticals, Inc is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). By volume, KPC sits between Korea (CENTER FOR Disease Control AND PREVENTION) and Krdc Ltd..

KPC's three-year grant acceleration

KPC Pharmaceuticals, Inc shows 2 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at KPC's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows KPC holds 5 patents at rank #48,138, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near KPC

By rank, the assignees closest to #48,138 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in KPC's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for KPC, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (38 here).

KPC's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 42% higher than 58% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

1 20172019202220232025 1
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
KPC Pharmaceuticals, Inc patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 20.0%
2019 1 20.0%
2022 1 20.0%
2023 1 20.0%
2025partial year 1 20.0%

Where it ranks

Overall rank by patents

#48,221

of 49,997 tracked assignees

Innovation Score

37.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

KPC Pharmaceuticals, Inc's patent record in context - here's where to go next.

  • KPC Pharmaceuticals, Inc's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #48,221 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare KPC Pharmaceuticals, Inc against Korea (CENTER FOR Disease Control AND PREVENTION), an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 37.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.